Literature DB >> 32886936

Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients.

Maria J Lizardo-Thiebaud1, Eduardo Cervantes-Alvarez2,3, Nathaly Limon-de la Rosa2, Farid Tejeda-Dominguez1, Mildred Palacios-Jimenez2,4, Osvely Méndez-Guerrero2, Marco Delaye-Martinez2,3, Fatima Rodriguez-Alvarez2,4, Beatriz Romero-Morales2, Wei-Hui Liu5, Christene A Huang6, David Kershenobich2, Nalu Navarro-Alvarez1,2,6.   

Abstract

Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32886936     DOI: 10.1055/s-0040-1715108

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  10 in total

1.  Practical points that gastrointestinal fellows should know in management of COVID-19.

Authors:  Tevhide Sahin; Cem Simsek; Hatice Yasemin Balaban
Journal:  World J Clin Cases       Date:  2022-06-06       Impact factor: 1.534

2.  Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis.

Authors:  Nathaly Limon-De La Rosa; Eduardo Cervantes-Alvarez; Nalu Navarro-Alvarez
Journal:  Clin Gastroenterol Hepatol       Date:  2021-09-02       Impact factor: 13.576

Review 3.  COVID-19 and liver dysfunction: What nutritionists need to know.

Authors:  Ming-Ke Wang; Xue-Lu Yu; Li-Yun Zhou; Hong-Mei Si; Ju-Fen Hui; Deng-Yong Hou; Wei-Peng Li; Ji-Shun Yang
Journal:  World J Gastroenterol       Date:  2022-04-21       Impact factor: 5.374

Review 4.  Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment.

Authors:  Cinzia Maria Chinnici; Giovanna Russelli; Matteo Bulati; Vitale Miceli; Alessia Gallo; Rosalia Busà; Rosaria Tinnirello; Pier Giulio Conaldi; Gioacchin Iannolo
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

5.  COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection.

Authors:  Silviu Guler-Margaritis; Adriana Mercan-Stanciu; Letitia Toma; Daniel Rusie; Teodora Isac; Mihai Dodot; Anca Zgura; Nicolae Bacalbasa; Bogdan Haineala; Dumitru Cristinel Badiu; Dragos Serban; Elena Laura Iliescu
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 6.  Liver injury in the era of COVID-19.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2021-02-07       Impact factor: 5.742

Review 7.  Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients.

Authors:  Liqin Yao; Lingeng Lu; Wenxue Ma
Journal:  Heliyon       Date:  2022-04-26

8.  Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection.

Authors:  Lidia Canillas; Teresa Broquetas; José A Carrión; Giulia Pagano; Agnès Soriano; Esther Garrido; Rosa Fernández; Ana Viu; Judit Romero; Gemma Díaz; Nuria Cañete; Susana Coll; Dolores Naranjo; Xavier Bessa; Montserrat Garcia-Retortillo; Marc Puigvehí
Journal:  J Viral Hepat       Date:  2022-06-26       Impact factor: 3.517

Review 9.  COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases-A Concise Review.

Authors:  Jorge Aquino-Matus; Misael Uribe; Norberto Chavez-Tapia
Journal:  Trop Med Infect Dis       Date:  2022-08-16

Review 10.  The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline.

Authors:  Jeffrey D Pyne; Adam M Brickman
Journal:  Neurodegener Dis       Date:  2021-07-28       Impact factor: 2.977

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.